Media coverage about Johnson & Johnson (NYSE:JNJ) has been trending very negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Johnson & Johnson earned a media sentiment score of -3.52 on their scale. InfoTrie also gave press coverage about the company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Johnson & Johnson’s analysis:
- Chinese Covid-19 Vaccine Trial Results Are a Good Sign for J&J and AstraZeneca’s Efforts (finance.yahoo.com)
- Coronavirus latest: Friday, May 22 (finance.yahoo.com)
- Johnson & Johnson (NYSE:JNJ) Receiving Very Critical Media Coverage, Report Finds (americanbankingnews.com)
- Pharma Stock Roundup: FDA Ok’s Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales (finance.yahoo.com)
- The race for a coronavirus treatment is fanning fears of ‘vaccine nationalism’ (finance.yahoo.com)
NYSE:JNJ opened at $144.37 on Friday. The firm’s 50 day simple moving average is $146.81 and its 200 day simple moving average is $142.30. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.31 and a quick ratio of 1.05. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The company has a market cap of $386.52 billion, a PE ratio of 19.10, a P/E/G ratio of 3.19 and a beta of 0.71.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be given a $1.01 dividend. The ex-dividend date is Friday, May 22nd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.80%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s payout ratio is 43.78%.
Several equities research analysts recently issued reports on the stock. Raymond James lifted their price target on shares of Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Barclays lifted their price target on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Finally, Argus reaffirmed a “buy” rating and set a $155.00 price target (down from $165.00) on shares of Johnson & Johnson in a report on Friday, March 27th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $163.47.
In other news, Director William D. Perez purchased 500 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were purchased at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the transaction, the director now owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.27% of the stock is currently owned by insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Market Indexes
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.